Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy.

Greenberg DP, Walker RE, Lee MS, Reisinger KS, Ward JI, Yogev R, Blatter MM, Yeh SH, Karron RA, Sangli C, Eubank L, Coelingh KL, Cordova JM, August MJ, Mehta HB, Chen W, Mendelman PM.

J Infect Dis. 2005 Apr 1;191(7):1116-22. Epub 2005 Feb 22.

PMID:
15747247
2.

Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants.

Lee MS, Greenberg DP, Yeh SH, Yogev R, Reisinger KS, Ward JI, Blatter MM, Cho I, Holmes SJ, Cordova JM, August MJ, Chen W, Mehta HB, Coelingh KL, Mendelman PM.

J Infect Dis. 2001 Oct 1;184(7):909-13. Epub 2001 Aug 15.

PMID:
11509996
3.

Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children.

Englund JA, Karron RA, Cunningham CK, Larussa P, Melvin A, Yogev R, Handelsman E, Siberry GK, Thumar B, Schappell E, Bull CV, Chu HY, Schaap-Nutt A, Buchholz U, Collins PL, Schmidt AC; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1096 Study Group.

Vaccine. 2013 Nov 19;31(48):5706-12. doi: 10.1016/j.vaccine.2013.09.046. Epub 2013 Oct 5.

4.

Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children.

Belshe RB, Newman FK, Anderson EL, Wright PF, Karron RA, Tollefson S, Henderson FW, Meissner HC, Madhi S, Roberton D, Marshall H, Loh R, Sly P, Murphy B, Tatem JM, Randolph V, Hackell J, Gruber W, Tsai TF.

J Infect Dis. 2004 Dec 15;190(12):2096-103. Epub 2004 Nov 8.

PMID:
15551207
5.

Current status of vaccines for parainfluenza virus infections.

Sato M, Wright PF.

Pediatr Infect Dis J. 2008 Oct;27(10 Suppl):S123-5. doi: 10.1097/INF.0b013e318168b76f. Review.

PMID:
18820572
6.

A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants.

Karron RA, Belshe RB, Wright PF, Thumar B, Burns B, Newman F, Cannon JC, Thompson J, Tsai T, Paschalis M, Wu SL, Mitcho Y, Hackell J, Murphy BR, Tatem JM.

Pediatr Infect Dis J. 2003 May;22(5):394-405.

PMID:
12792378
7.

Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants.

Karron RA, Makhene M, Gay K, Wilson MH, Clements ML, Murphy BR.

Pediatr Infect Dis J. 1996 Aug;15(8):650-4.

PMID:
8858666
8.

Determinants of the host range restriction of replication of bovine parainfluenza virus type 3 in rhesus monkeys are polygenic.

Skiadopoulos MH, Schmidt AC, Riggs JM, Surman SR, Elkins WR, St Claire M, Collins PL, Murphy BR.

J Virol. 2003 Jan;77(2):1141-8.

9.

A randomized, double-blind, placebo-controlled, phase 1/2a study of the safety and immunogenicity of a live, attenuated human parainfluenza virus type 3 vaccine in healthy infants.

Bernstein DI, Falloon J, Yi T.

Vaccine. 2011 Sep 16;29(40):7042-8. doi: 10.1016/j.vaccine.2011.07.031. Epub 2011 Jul 22.

PMID:
21782874
10.

A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children.

Karron RA, Wright PF, Newman FK, Makhene M, Thompson J, Samorodin R, Wilson MH, Anderson EL, Clements ML, Murphy BR, et al.

J Infect Dis. 1995 Dec;172(6):1445-50.

PMID:
7594701
11.

Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.

Belshe RB, Newman FK, Tsai TF, Karron RA, Reisinger K, Roberton D, Marshall H, Schwartz R, King J, Henderson FW, Rodriguez W, Severs JM, Wright PF, Keyserling H, Weinberg GA, Bromberg K, Loh R, Sly P, McIntyre P, Ziegler JB, Hackell J, Deatly A, Georgiu A, Paschalis M, Wu SL, Tatem JM, Murphy B, Anderson E.

J Infect Dis. 2004 Feb 1;189(3):462-70. Epub 2004 Jan 20.

PMID:
14745704
12.

Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children.

Gomez M, Mufson MA, Dubovsky F, Knightly C, Zeng W, Losonsky G.

Pediatr Infect Dis J. 2009 Jul;28(7):655-8. doi: 10.1097/INF.0b013e318199c3b1.

PMID:
19483659
13.

A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children.

Karron RA, Wright PF, Hall SL, Makhene M, Thompson J, Burns BA, Tollefson S, Steinhoff MC, Wilson MH, Harris DO, et al.

J Infect Dis. 1995 May;171(5):1107-14.

PMID:
7751684
14.

The cDNA-derived investigational human parainfluenza virus type 3 vaccine rcp45 is well tolerated, infectious, and immunogenic in infants and young children.

Karron RA, Casey R, Thumar B, Surman S, Murphy BR, Collins PL, Schmidt AC.

Pediatr Infect Dis J. 2011 Oct;30(10):e186-91. doi: 10.1097/INF.0b013e31822ea24f.

15.

Phase I, randomized, controlled trial to study the reactogenicity and immunogenicity of a nasal, inactivated trivalent influenza virus vaccine in healthy adults.

Halperin SA, Smith B, Clarke K, Treanor J, Mabrouk T, Germain M.

Hum Vaccin. 2005 Jan-Feb;1(1):37-42. Epub 2005 Jan 12.

PMID:
17038827
16.

Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children.

Bernstein DI, Malkin E, Abughali N, Falloon J, Yi T, Dubovsky F; MI-CP149 Investigators.

Pediatr Infect Dis J. 2012 Feb;31(2):109-14. doi: 10.1097/INF.0b013e31823386f1.

PMID:
21926667
17.

Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults.

Slobod KS, Shenep JL, Luján-Zilbermann J, Allison K, Brown B, Scroggs RA, Portner A, Coleclough C, Hurwitz JL.

Vaccine. 2004 Aug 13;22(23-24):3182-6.

PMID:
15297072
18.

Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children.

Karron RA, Thumar B, Schappell E, Surman S, Murphy BR, Collins PL, Schmidt AC.

Vaccine. 2012 Jun 6;30(26):3975-81. doi: 10.1016/j.vaccine.2011.12.022. Epub 2011 Dec 14.

19.

Half-life of human parainfluenza virus type 3 (hPIV3) maternal antibody and cumulative proportion of hPIV3 infection in young infants.

Lee MS, Mendelman PM, Sangli C, Cho I, Mathie SL, August MJ.

J Infect Dis. 2001 Apr 15;183(8):1281-4. Epub 2001 Mar 26.

PMID:
11262213

Supplemental Content

Support Center